Noile-Immune Biotech Inc. (JP:4893)

:4893

4893

Noile-Immune Biotech Inc.

RESEARCH TOOLSreports

Want to see JP:4893 full AI Analyst Report?

Noile-Immune Biotech Inc. (4893) Price & Analysis

0 Followers

4893 Stock Chart & Stats

¥134.00

¥9.00(4.81%)

At close: Jan 08 4:00 PM EST

¥134.00

¥9.00(4.81%)

Day’s Range― - ―

52-Week Range¥126.00 - ¥217.00

Previous CloseN/A

Volume1.93M

Average Volume (3M)85.17K

Market Cap

¥6.58B

Enterprise Value¥2.58B

Total Cash (Recent Filing)¥4.31B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta1.37

Next Earnings

May 19, 2026

EPS Estimate

-5.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.36

Shares Outstanding43,276,764

10 Day Avg. Volume110,290

30 Day Avg. Volume85,173

Financial Highlights & Ratios

PEG Ratio0.41

Price to Book (P/B)1.46

Price to Sales (P/S)1151.82

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-34

Revenue Forecast (FY)¥300.00M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA debt-free capital structure materially lowers solvency and interest risks, preserving financial flexibility to fund clinical programs or negotiate partnerships. Over 2–6 months this reduces the chance of near-term distress and supports strategic choices without immediate refinancing pressure.

Very High Gross MarginsConsistently near-100% gross margins imply strong unit economics for the company’s therapies, providing attractive operating leverage if revenues scale. This structural margin strength can absorb R&D and commercialization spend and improve long-term profitability once clinical success drives higher sales or licensing.

Focused Cell-therapy R&D PlatformA proprietary cell-based immunotherapy focus targets a structural growth market in oncology and provides clear IP-led differentiation. A small, specialized team (25 employees) supports nimble R&D and makes the company an attractive partner or acquisition target if clinical milestones are met, sustaining long-term strategic optionality.

Bears Say

Sharply Contracting RevenueRapid and significant revenue contraction undermines operating leverage and the company’s ability to fund development internally. Persistent top-line declines weaken commercial credibility, increase dependency on external funding or partners, and raise execution risk for multi-year clinical programs over the medium term.

Persistent Negative Operating Cash FlowConsistent negative operating cash flow means the business cannot self-fund its development cycle, forcing reliance on equity or partnership financing. Continued cash burn depletes equity over time, increases dilution risk, and constrains strategic choices unless structural cash generation improves or external funding is secured.

Large, Sustained Net Losses And Negative ROELong-running net losses and negative ROE indicate the company is not generating returns on invested capital, eroding shareholder equity. This persistent unprofitability raises the cost and scarcity of capital, making future funding more dilutive and impairing the company’s ability to invest in growth without external support.

4893 FAQ

What was Noile-Immune Biotech Inc.’s price range in the past 12 months?

Noile-Immune Biotech Inc. lowest stock price was ¥126.00 and its highest was ¥217.00 in the past 12 months.

What is Noile-Immune Biotech Inc.’s market cap?

Noile-Immune Biotech Inc.’s market cap is ¥6.58B.

When is Noile-Immune Biotech Inc.’s upcoming earnings report date?

Noile-Immune Biotech Inc.’s upcoming earnings report date is May 19, 2026 which is in 17 days.

How were Noile-Immune Biotech Inc.’s earnings last quarter?

Noile-Immune Biotech Inc. released its earnings results on Feb 13, 2026. The company reported -¥4.36 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.36.

Is Noile-Immune Biotech Inc. overvalued?

According to Wall Street analysts Noile-Immune Biotech Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Noile-Immune Biotech Inc. pay dividends?

Noile-Immune Biotech Inc. does not currently pay dividends.

What is Noile-Immune Biotech Inc.’s EPS estimate?

Noile-Immune Biotech Inc.’s EPS estimate is -5.05.

How many shares outstanding does Noile-Immune Biotech Inc. have?

Noile-Immune Biotech Inc. has 43,276,764 shares outstanding.

What happened to Noile-Immune Biotech Inc.’s price movement after its last earnings report?

Noile-Immune Biotech Inc. reported an EPS of -¥4.36 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.938%.

Which hedge fund is a major shareholder of Noile-Immune Biotech Inc.?

Currently, no hedge funds are holding shares in JP:4893

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Noile-Immune Biotech Inc.

Noile-Immune Biotech Inc. researches and develops CAR-T cells for cancer immunotherapies. The company was incorporated in 2015 and is headquartered in Minato, Japan.